Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome

Clinical and Translational Gastroenterology

Volumn 7, Issue , 2016, Pages

  Schwartz, Lauren K ^a   O'Keefe, Stephen J D ^b   Fujioka, Ken ^c   Gabe, Simon M ^d   Lamprecht, Georg ^e   Pape, Ulrich Frank ^f   Li, Benjamin ^g   Youssef, Nader N ^g,i   Jeppesen, Palle B ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SCRIPPS CLINIC   (United States)

^d ST MARK S HOSPITAL   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER ROSTOCK   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g NPS Pharmaceuticals   (United States)

^h Rigshospitalet   (Denmark)

ⁱ Digestive HealthCare Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CITRULLINE; PLACEBO; TEDUGLUTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; CATHETER INFECTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLATULENCE; GASTROENTERITIS; HEADACHE; HEALTH STATUS; HUMAN; HYPERSENSITIVITY; HYPERVOLEMIA; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NUTRITIONAL STATUS; OPEN STUDY; PARENTERAL NUTRITION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SHORT BOWEL SYNDROME; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER EXTREMITY DEEP VEIN THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 84957544265     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.69     Document Type: Article

References (34)

1. Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr 2014; 38: 8S-13S.
2. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124: 1111-1134.
3. Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 2006; 130: S52-S59.
4. Tappenden KA. Intestinal adaptation following resection. JPEN J Parenter Enteral Nutr 2014; 38: 23S-31S.
5. Matarese LE. Nutrition and fluid optimization for patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2013; 37: 161-170.
6. O'Keefe SJ, Buchman AL, Fishbein TM et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006; 4: 6-10.
7. Kelly DG, Tappenden KA, Winkler MF. Short bowel syndrome: highlights of patient management, quality of life, and survival. JPEN J Parenter Enteral Nutr 2014; 38: 427-437.
8. Cavicchi M, Beau P, Crenn P et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132: 525-532.
9. Gillanders L, Angstmann K, Ball P et al. A prospective study of catheter-related complications in HPN patients. Clin Nutr 2012; 31: 30-34.
10. Winkler MF, Smith CE. Clinical, social, and economic impacts of home parenteral =nutrition dependence in short bowel syndrome. JPEN J Parenter Enteral Nutr 2014; 38: 32S-37S.
11. Staun M, Pironi L, Bozzetti F et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr 2009; 28: 467-479.
12. Dreesen M, Foulon V, Spriet I et al. Epidemiology of catheter-related infections in adult patients receiving home parenteral nutrition: a systematic review. Clin Nutr 2013; 32: 16-26.
13. Carlsson E, Bosaeus I, Nordgren S. Quality of life and concerns in patients with short bowel syndrome. Clin Nutr 2003; 22: 445-452.
14. Matarese LE, Jeppesen PB, O'Keefe SJ. Short bowel syndrome in adults: the need for an interdisciplinary approach and coordinated care. JPEN J Parenter Enteral Nutr 2014; 38: 60S-64S.
15. Kumpf VJ. Pharmacologic management of diarrhea in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2014; 38: 38S-44S.
16. Byrne TA, Wilmore DW, Iyer K et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 2005; 242: 655-661.
17. Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143: 1473-1481.
18. Orskov C, Holst JJ, Knuhtsen S et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467-1475.
19. Drucker DJ, Erlich P, Asa SL et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93: 7911-7916.
20. Jeppesen PB, Sanguinetti EL, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224-1231.
21. Jeppesen PB, Gilroy R, Pertkiewicz M et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60: 902-914.
22. Kalaitzakis E, Carlsson E, Josefsson A et al. Quality of life in short-bowel syndrome: impact of fatigue and gastrointestinal symptoms. Scand J Gastroenterol 2008; 43: 1057-1065.
23. Grunkemeier DM, Cassara JE, Dalton CB et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5: 1126-1139.
24. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res 1994; 54: 5284-5295.
25. Hodgson DC, Gilbert ES, Dores GM et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25: 1489-1497.
26. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
27. Rex DK, Bond JH, Winawer S et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2002; 97: 1296-1308.
28. GATTEX® (teduglutide [rDNA origin]). Full Prescribing Information, NPS Pharmaceuticals, Inc., Bedminster, NJ, 2014.
29. Hankins J. The role of albumin in fluid and electrolyte balance. J Infus Nurs 2006; 29: 260-265.
30. Dibb M, Teubner A, Theis V et al. Review article: the management of long-term parenteral nutrition. Aliment Pharmacol Ther 2013; 37: 587-603.
31. Jeppesen PB, Pertkiewicz M, Forbes A et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide - analyses from a randomised, placebo-controlled study. Clin Nutr 2013; 32: 713-721.
32. Seidner DL, Schwartz LK, Winkler MF et al. Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure. JPEN J Parenter Enteral Nutr 2013; 37: 201-211.
33. Amiot A, Messing B, Corcos O et al. Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. Clin Nutr 2013; 32: 368-374.
34. Pironi L, Forbes A, Joly F et al. Survival of patients identified as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterology 2008; 135: 61-71.